메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Feng Jun (Department of Critical Care Medicine Tongji Hospital Tongji Medical College Huazhong University of) Fang Bangjiang (Department of Emergency Medicine LongHua Hospital Shanghai University of Traditional Chinese Medici) Zhou Daixing (Department of Critical Care Medicine Tongji Hospital Tongji Medical College Huazhong University of) Wang Junshuai (Department of Critical Care Medicine Tongji Hospital Tongji Medical College Huazhong University of) Zou Dengxiu (Department of Critical Care Medicine Tongji Hospital Tongji Medical College Huazhong University of) Yu Gang (Department of Critical Care Medicine Tongji Hospital Tongji Medical College Huazhong University of) Fen Yikuan (Department of Critical Care Medicine Tongji Hospital Tongji Medical College Huazhong University of) Peng Dan (Department of Critical Care Medicine Tongji Hospital Tongji Medical College Huazhong University of) Hu Jifa (Office of Academic Research Tongji Hospital Tongji Medical College Huazhong University of Science a) Zhan Daqian (Department of Critical Care Medicine Tongji Hospital Tongji Medical College Huazhong University of)
저널정보
한국미생물생명공학회 Journal of Microbiology and Biotechnology Journal of Microbiology and Biotechnology 제31권 제3호
발행연도
2021.1
수록면
380 - 386 (7page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
The coronavirus disease 2019 (COVID-19) pandemic has become a public health emergency of global concern. In China, traditional Chinese medicine has been widely administered to COVID-19 patients without sufficient evidence. To evaluate the efficacy of Shenhuang Granule (SHG) for treating critically ill patients with COVID-19, we included in this study 118 patients who were admitted to the ICU of Tongji Hospital between January 28, 2020 and March 28, 2020. Among these patients, 33 (27.9%) received standard care plus SHG (treatment group) and 85 (72.1%) received standard care alone (control group). Enrolled patients had a median (IQR) age of 68 (57-75) years, and most (79 [67.1%]) were men. At end point of this study, 83 (70.3%) had died in ICU, 29 (24.5%) had been discharged from ICU, and 6 patients (5.2%) were still in ICU. Compared with control group, mortality was significantly lower in treatment group (45.4% vs. 80%, p < .001). Patients in treatment group were less likely to develop acute respiratory distress syndrome (ARDS) (12 [36.3%] vs. 54 [63.5%], p = 0.012) and cardiac injury (5 [15.1%] vs. 32 [37.6%], p = 0.026), and less likely to receive mechanical ventilation (22 [66.7%] vs. 72 [84.7%], p = 0.028) than those in control group. The median time from ICU admission to discharge was shorter in treatment group (32 [20?73] days vs. 76 [63?79] days, p = 0.0074). These findings suggest that SHG treatment as a complementary therapy might be effective for critically ill adults with COVID-19 and warrant further clinical trials.

목차

등록된 정보가 없습니다.

참고문헌 (33)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0